Inhibition and induction of human cytochrome P450 (CYP) enzymes.
about
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell lineEvaluation of 7-benzyloxy-4-trifluoromethylcoumarin, some other 7-hydroxy-4-trifluoromethylcoumarin derivatives and 7-benzyloxyquinoline as fluorescent substrates for rat hepatic cytochrome P450 enzymesUse of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases.Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2.Cardiac safety of ophthalmic timolol.Inhibition of Carcinogen-Activating Cytochrome P450 Enzymes by Xenobiotic Chemicals in Relation to Antimutagenicity and Anticarcinogenicity.Cytochrome P450 2E1: its clinical and toxicological role.Evaluation of metabolism-mediated herb-drug interactions.Biotransformation of xenobiotics by amine oxidases.Human CYPs: in vivo and clinical aspects.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism.Interactions of herbs with cytochrome P450.Drug-activated nuclear receptors CAR and PXR.Watson and Crick 50 years on. From double helix to pharmacogenomics.Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.Prediction of drug metabolism and interactions on the basis of in vitro investigations.Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in miceAntidepressant-drug interactions are potentially but rarely clinically significant.Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies.In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22)Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations.Mode-of-action analysis for induction of rat liver tumors by pyrethrins: relevance to human cancer risk.Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation.Metabolism of ophthalmic timolol: new aspects of an old drug.Cytochrome P450-activated prodrugs.Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.The effect of thiacloprid formulation on DNA/chromosome damage and changes in GST activity in bovine peripheral lymphocytes.An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.Recent updates in utilizing prodrugs in drug delivery (2013-2015).No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants.The effects of mebendazole on P4501A activity in rat hepatocytes and HepG2 cells. Comparison with tiabendazole and omeprazole.Role of cytochrome P450-dependent monooxygenases and polymorphic variants of GSTT1 and GSTM1 genes in the formation of brain lesions in individuals chronically exposed to mercury.Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems.
P2860
Q28371944-2BC4FD3A-1126-499D-B781-BC8FC48DB162Q28579888-CD946701-1F80-4909-AB26-C1459D0843CBQ31900846-69EC9F1A-A0C7-40D5-8E10-BD4ACA1CC941Q32081610-35FFD114-0633-41FA-BD63-460B6EEB5C21Q33167596-C2B7116F-5AAA-4BDB-BADD-92617FA0148CQ33596274-596B086F-9B34-4B17-949B-8506F0B9ED1EQ33962207-8D8AC569-10ED-4669-B2EE-F625D80555A3Q34238039-6EFD0F1B-A1F1-4A53-943B-E06FAC98F8B3Q34316455-E145AD23-6444-4330-84C8-10F36398533EQ34627903-FC087C6C-DB79-4CF2-8AAE-BD911228A119Q35027930-5FB6759C-7AD5-4CDA-8EB2-94C5181756E7Q35085025-05708DF5-220F-4528-8E06-B5DAF9C71CE0Q35085032-EC09FC79-2C69-4EF1-A33A-7B4A5A02932DQ35160978-B5CEE2DD-B049-427D-9E17-0E2FB73F7442Q35630029-9B2C06E7-B7F0-4F97-A2D2-9C270ADF2AACQ35863379-4B13228B-BAF7-441E-9FB4-8EF7441C8F8BQ36012329-F1741321-34BB-48E4-A7FF-A8C7BA4602F2Q36055339-7F9502A7-70D8-4BCF-A223-C9F673967671Q36055562-4063D07B-BF81-433B-99F6-2774B161526DQ36471008-8915C228-2C91-47E6-AF27-88ACBF545F96Q36538987-968B549E-2426-4439-9C00-76519EB0FD0BQ36546250-2B13EFF8-C4EF-4F80-9FCA-438CB232BC27Q36700587-AF87B592-18BD-4CCA-A4AB-5FBC08631B72Q36703818-02819F88-172F-414E-B4AE-5F5DF8D94DFCQ36960535-EF975914-75D6-4C9E-B17C-6F998FF6D838Q36985051-86940B46-1FC1-47C1-ADEF-ED04344D7A10Q37492574-D26EB64D-6E5D-4A7E-918D-355984005138Q37557621-292A704D-5539-4FE2-AA72-FB401DD92A73Q37850837-D988F389-C534-44B0-A880-0BB89CCACB05Q38077550-978A19A1-E54F-45DA-B9D6-D26156ED37F7Q38307447-22C4B5D8-1AD4-4239-8CFB-09FBC6507B52Q38413073-F876DA4B-05EF-4AD8-A19D-4FFC780155D0Q38598487-C5FEF3A6-5C80-4672-BDDD-169B1EE2A7BDQ38702949-0741D7A9-1F0B-4DA7-9E35-544C309DA727Q39810172-8DC8BA04-ABD7-40EC-AFB5-D492DAE920E8Q41104952-50EAD66E-F6AC-491D-ADDF-59D356D3D4E8Q41959654-3BFE23C3-655A-429B-B754-DEA956B5915DQ42166558-0B576E6B-13A9-497D-9DCD-8F05A2A19F67Q42708000-915243BB-7FC8-400E-AD56-9C873BAFD441Q43712808-478C5539-3063-41C6-BE38-07CEC9274540
P2860
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@ast
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@en
Inhibition and induction of human cytochrome P450
@nl
type
label
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@ast
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@en
Inhibition and induction of human cytochrome P450
@nl
prefLabel
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@ast
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@en
Inhibition and induction of human cytochrome P450
@nl
P2093
P356
P1433
P1476
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
@en
P2093
Pelkonen O
Taavitsainen P
P304
P356
10.1080/004982598238886
P407
P577
1998-12-01T00:00:00Z